Evaluation of serum soluble OX40 ligand as a prognostic indicator in acute coronary syndrome patients

Clinica Chimica Acta

Volumn 411, Issue 21-22, 2010, Pages 1662-1665

  Yan, Jinchuan ^a   Gong, Jie ^a   Chen, Guanghua ^a   Liu, Peijing ^a   Wang, Cuiping ^a   Yang, Ping ^a  

^a AFFILIATED HOSPITAL OF JIANGSU UNIVERSITY   (China)

Author keywords

Acute coronary syndromes; Atherosclerosis; OX40 ligand

Indexed keywords

OX40 LIGAND; TROPONIN I;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ADULT; ANGINA PECTORIS; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; SUDDEN DEATH; THORAX PAIN; THROMBOCYTE ACTIVATION;

ACUTE CORONARY SYNDROME; AGED; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; CHEST PAIN; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; OX40 LIGAND; PLATELET ACTIVATION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; TROPONIN T;

ANGINA;

EID: 77956473196     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2010.06.016     Document Type: Article

References (17)

1. Morrow D.A., Cannon C.P., Jesse R.L., Newby L.K., Ravkilde J., Storrow A.B., et al. National Academy of Clinical Biochemistry Laboratory Medicine practice guidelines: clinical characteristics and utilization of biochemical markers in acute coronary syndromes. Clin Chem 2007, 53:552-574.
2. Thygesen K., Alpert J.S., White H.D. Joint ESC/AACF/AHA/WHF task force for the redefinition of myocardial infarction, universal definition of myocardial infarction. J Am Coll Cardiol 2007, 50:2173-2195.
3. Kaul P., Chang W.C., Westerhout C.M., Graham M.M., Armstrong P.W. Differences in admission rates and outcomes between men and women presenting to emergency departments with coronary syndromes. CMAJ 2007, 177:1193-1199.
4. Bonaca M.P., Morrow D.A. Defining a role for novel biomarkers in acute coronary syndromes. Clin Chem 2008, 54:1424-1431.
5. Varo N., de Lemos J.A., Libby P., Morrow D.A., Murphy S.A., Nuzzo R., et al. Soluble CD40L: risk prediction after acute coronary syndromes. Circulation 2003, 108(9):1049-1052.
6. Kavsak P.A., Wang X., Henderson M., Ko D.T., MacRae A.R., Jaffe A.S. PAPP-A as a marker of increased long-term risk in patients with chest pain. Clin Biochem 2009, 42:1012-1018.
7. Ria M., Eriksson P., Boquist S., Ericsson C.G., Hamsten A., Lagercrantz J. Human genetic evidence that OX40 is implicated in myocardial infarction. Biochem Biophy Res Com 2006, 339:1001-1006.
8. Wang X., Ria M., Kelmenson P.M., Eriksson P., Higgins D.C., Samnegard C., et al. Positional identification of TNFSF4, encoding OX40 ligand, as a gene that influences atherosclerosis susceptibility. Nat Genet 2005, 37:365-372.
9. Michelson A.D., Barnard M.R., Krueger L.A., Valeri C.R., Furman M.I. Circulating monocyte-platelet aggregates are a more sensitive marker of in vivo platelet activation than platelet surface P-selectin: studies in baboons, human coronary intervention, and human acute myocardial infarction. Circulation 2001, 104:1533-1537.
10. Liu B., Yu G., Yang Z., Sun L., Song R., Liu F., et al. Simvastatin reduces OX40 and OX40 ligand expression in human peripheral blood mononuclear cells and in patients with atherosclerotic cerebral infarction. J Int Med Res 2009, 37:601-610.
11. van Wanrooij E.J., van Puijvelde G.H., de Vos P., Yagita H., van Berkel T.J., Kuiper J. Interruption of the Tnfrsf4/Tnfsf4 (OX40/OX40L) pathway attenuates atherogenesis in low-density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol 2007, 27:204-210.
12. Yan J., Chen G., Gong J., Wang C., Du R. Upregulation of OX40-OX40 ligand system on T lymphocytes in patients with acute coronary syndromes. J Cardiovasc Pharmacol 2009, 54:451-455.
13. Liu D.M., Yan J.C., Wang C.P., Chen G.H., Ding S., Liu P.J., et al. The clinical implications of increased OX40 ligand expression in patients with acute coronary syndrome. Clin Chim Acta 2008, 397:22-26.
14. Alpert J.S., Thygesen K., Antman E., Bassand J.P. Myocardial infarction redefined-a consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition ofmyocardial infarction. J Am Coll Cardiol 2000, 36:959-969.
15. Thygesen K., Alpert J.S., White H.D. Joint ESC/ACCF/AHA/WHF task force for the redefinition of myocardial Infarction, universal definition of myocardial infarction. Eur Heart J 2007, 28:2525-2538.
16. Yan J., Wang C., Du R., Liu P., Chen G. OX40-OX40 ligand interaction may activate phospholipase C signal transduction pathway in human umbilical vein endothelial cells. Chem Biol Interact 2009, 180:460-464.
17. Dominguez-Rodriguez A., Abreu-Gonzalez P., Kaski J.C. Inflammatory systemic biomarkers in setting acute coronary syndromes - effects of the diurnal variation. Curr Drug Targets 2009, 10:1001-1008.